Heidi Overton’s FDA nomination, 4-OH-DiPT research, and the challenges of bringing psychedelic therapy into routine care

Heidi Overton’s nomination to lead the FDA could influence U.S. psychedelic policy, including implementation of President Trump’s support for accelerating access to psychedelic treatments and ibogaine medicalization. Her confirmation remains uncertain because of Senate concerns about limited managerial experience and her role in a childhood vaccine executive order. The newsletter also covers a UMass Chan clinical trial testing 4-OH-DiPT, a fast-acting, shorter-lasting synthetic analog of psilocin, for adjustment disorder, and reviews evidence that psilocybin therapy may be feasible in public mental health services, while noting limitations including an unusually highly educated participant group. A Nature Mental Health commentary argues that psychiatric pharmacists could improve safety, address drug interactions and workforce shortages, and help shape regulation. The issue also highlights risks associated with psychedelic medical tourism and underground clinics, alongside other psychedelic news and research developments.